These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23723255)

  • 1. The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.
    Johansson M; Oudin A; Tiemann K; Bernard A; Golebiewska A; Keunen O; Fack F; Stieber D; Wang B; Hedman H; Niclou SP
    Neuro Oncol; 2013 Sep; 15(9):1200-11. PubMed ID: 23723255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma.
    Neirinckx V; Hau AC; Schuster A; Fritah S; Tiemann K; Klein E; Nazarov PV; Matagne A; Szpakowska M; Meyrath M; Chevigné A; Schmidt MHH; Niclou SP
    Neurooncol Adv; 2019; 1(1):vdz024. PubMed ID: 32642659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
    Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
    J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
    Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
    PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.
    Longo SL; Padalino DJ; McGillis S; Petersen K; Schirok H; Politz O; Canute GW; Post DE
    Invest New Drugs; 2012 Dec; 30(6):2161-72. PubMed ID: 22203214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
    Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
    Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth.
    Karkare S; Chhipa RR; Anderson J; Liu X; Henry H; Gasilina A; Nassar N; Ghosh J; Clark JP; Kumar A; Pauletti GM; Ghosh PK; Dasgupta B
    Clin Cancer Res; 2014 Jan; 20(1):199-212. PubMed ID: 24170547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.
    Auf G; Jabouille A; Delugin M; Guérit S; Pineau R; North S; Platonova N; Maitre M; Favereaux A; Vajkoczy P; Seno M; Bikfalvi A; Minchenko D; Minchenko O; Moenner M
    BMC Cancer; 2013 Dec; 13():597. PubMed ID: 24330607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    Estrada-Bernal A; Lawler SE; Nowicki MO; Ray Chaudhury A; Van Brocklyn JR
    J Neurooncol; 2011 May; 102(3):353-66. PubMed ID: 20938717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
    Stutz MA; Shattuck DL; Laederich MB; Carraway KL; Sweeney C
    Oncogene; 2008 Sep; 27(43):5741-52. PubMed ID: 18542056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib and erlotinib inhibits growth of c-Met
    Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
    Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
    Suina K; Tsuchihashi K; Yamasaki J; Kamenori S; Shintani S; Hirata Y; Okazaki S; Sampetrean O; Baba E; Akashi K; Mitsuishi Y; Takahashi F; Takahashi K; Saya H; Nagano O
    Cancer Sci; 2018 Dec; 109(12):3874-3882. PubMed ID: 30298963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
    Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
    Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR signals to mTOR through PKC and independently of Akt in glioma.
    Fan QW; Cheng C; Knight ZA; Haas-Kogan D; Stokoe D; James CD; McCormick F; Shokat KM; Weiss WA
    Sci Signal; 2009 Jan; 2(55):ra4. PubMed ID: 19176518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of glioma proliferation through allosteric inhibition of JAK2.
    He K; Qi Q; Chan CB; Xiao G; Liu X; Tucker-Burden C; Wang L; Mao H; Lu X; McDonald FE; Luo H; Fan QW; Weiss WA; Sun SY; Brat DJ; Ye K
    Sci Signal; 2013 Jul; 6(283):ra55. PubMed ID: 23838182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.